On March 29, 2021 Ikena Oncology, Inc. (View Source Boston, MA, USA; CEO Mark Manfredi, Ikena Oncology) debuted as a public company, reported that listing its shares on the NASDAQ market on March 26, 2021 (Press release, AskAt, MAR 29, 2021, View Source [SID1234577230]). Ikena Oncology is currently developing AskAt’s EP4 antagonist, AAT-007, for immuno oncology therapy in the US. For further details, please see Ikena’s announcement (Ikena Oncology Public Offering).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!